Interim [18F]Fluorodeoxyglucose–Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer-Reference-Cited by-同舟云学术

Interim [18F]Fluorodeoxyglucose–Positron Emission Tomography During Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Published:2019-08-10 Issue:23 Volume:37 Page:2091-2092
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Hindié Elif¹,Groheux David¹

Affiliation:

1. Elif Hindié, MD, PhD, Bordeaux University Hospital, Bordeaux, France; and David Groheux, MD, PhD, Saint-Louis Hospital, Paris, France

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.19.00776

Reference9 articles.

1. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

2. HER2-overexpressing breast cancer: FDG uptake after two cycles of chemotherapy predicts the outcome of neoadjuvant treatment

3. Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial

4. 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

5. 18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply to E. Hindié et al;Journal of Clinical Oncology;2019-08-10